Antihyperlipidemic and antiapoptotic potential of zingerone on alcohol induced hepatotoxicity in experimental rats

Mani, Vijay; Arivalagan, S.; Siddique, Aktarul Islam; Nalini, Namasivayam

doi:10.1016/j.cbi.2017.04.019

Cited by 21 publications

(8 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zingerone produces anti-obesity effect by activating adipocyte lipolysis and Leads to hypolipidemia in alcohol-induced hepatotoxicity (Han, Morimoto, & Zheng, 2008;Mani, Arivalagan, Islam Siddique, & Namasivayam, 2017). In the present study zingerone supplementation in different treatment groups improved the levels of TC and TG ( Figure 5).…”

Section: Discussionsupporting

confidence: 50%

“…Ginger is known to cause hypolipidemia by activating an important pathway of conversion of cholesterol to bile acids, thus decreasing cholesterol levels (Khosravani et al, 2016). Zingerone produces anti‐obesity effect by activating adipocyte lipolysis and Leads to hypolipidemia in alcohol‐induced hepatotoxicity (Han, Morimoto, & Zheng, 2008; Mani, Arivalagan, Islam Siddique, & Namasivayam, 2017). In the present study zingerone supplementation in different treatment groups improved the levels of TC and TG (Figure 5).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Zingerone prevents lead‐induced toxicity in liver and kidney tissues by regulating the oxidative damage in Wistar rats

et al. 2020

View full text Add to dashboard Cite

Among the heavy metal poisonings, lead is considered as a major toxic metal causing hematological, neurological, immunological, hepatic, and renal dysfunctions. Lead causes inhibition of ALAD leading to the ALA accumulation inside the cells. Lead also leads to disruption of the anti-oxidative enzyme system, organ function, and lipid membranes of the cell causing oxidative stress. Zingerone, a phenolic alkanone, is an active edible ingredient present in the ginger that possess varied pharmacological properties. The aim of our study was to evaluate the protective effect of zingerone in lead-induced toxicity in wistar rats. ALAD concentration was improved in kidney and liver tissues treated with zingerone. Protective effect of zingerone was observed in terms of significant improvement in kidney and liver histology, anti-oxidant enzyme activity (CAT, SOD, GPx, and GR), organ function parameters, lipid profile, and decreased level of LPO. Therefore, zingerone pretreatment can be a promising agent for alleviation of lead-induced oxidative damage in cells. Practical applications Published reports have revealed that consumption of certain bioactive nutrients for example, flavonoids, mineral elements, and vitamins can offer defense from the environmental lead contamination. Zingerone is a strong anti-oxidant, with very less side effects and has exceptional property of scavenging free radicals, hence reducing the oxidative stresses. This fundamental property of zingerone can alone help in countering the heavy metal toxicity. Different groups have published reported numerous properties of zingerone but as per our understanding till date no study about alleviation of lead toxicity by zingerone in animal model has been undertaken. Hence, we conducted this research to explore the preventive effect of zingerone in lead induced kidney and liver toxicity. The outcome of our study shows potent anti-oxidant effect and ALAD modulatory property of zingerone which makes it suitable edible candidate for use in countering lead toxicity.

show abstract

Section: Discussionsupporting

confidence: 50%

Section: Discussionmentioning

confidence: 99%

Zingerone prevents lead‐induced toxicity in liver and kidney tissues by regulating the oxidative damage in Wistar rats

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Lpl, in turn, encodes for lipoprotein lipase, an endothelium-anchored enzyme that catalyzes the hydrolysis of triglycerides from chylomicrons and very low density lipoproteins (VLDL) into free fatty acids, enabling their uptake by extrahepatic tissues [ 199 , 200 , 201 ]. The decrease in Lpl expression, as seen upon exposure to 50 mg/kg tramadol and tapentadol, might therefore be associated with higher serum triglyceride levels—which is observed in tapentadol groups ( Figure 3 )—and higher serum cholesterol levels—as seen in the 50 mg/kg tramadol group ( Figure 3 )—as these lipids are transported in the form of lipoproteins.…”

Section: Discussionmentioning

confidence: 99%

Repeated Administration of Clinical Doses of Tramadol and Tapentadol Causes Hepato- and Nephrotoxic Effects in Wistar Rats

et al. 2020

View full text Add to dashboard Cite

Tramadol and tapentadol are fully synthetic and extensively used analgesic opioids, presenting enhanced therapeutic and safety profiles as compared with their peers. However, reports of adverse reactions, intoxications and fatalities have been increasing. Information regarding the molecular, biochemical, and histological alterations underlying their toxicological potential is missing, particularly for tapentadol, owing to its more recent market authorization. Considering the paramount importance of liver and kidney for the metabolism and excretion of both opioids, these organs are especially susceptible to toxicological damage. In the present study, we aimed to characterize the putative hepatic and renal deleterious effects of repeated exposure to therapeutic doses of tramadol and tapentadol, using an in vivo animal model. Male Wistar rats were randomly divided into six experimental groups, composed of six animals each, which received daily single intraperitoneal injections of 10, 25 or 50 mg/kg tramadol or tapentadol (a low, standard analgesic dose, an intermediate dose and the maximum recommended daily dose, respectively). An additional control group was injected with normal saline. Following 14 consecutive days of administration, serum, urine and liver and kidney tissue samples were processed for biochemical, metabolic and histological analysis. Repeated administration of therapeutic doses of both opioids led to: (i) increased lipid and protein oxidation in liver and kidney, as well as to decreased total liver antioxidant capacity; (ii) decreased serum albumin, urea, butyrylcholinesterase and complement C3 and C4 levels, denoting liver synthesis impairment; (iii) elevated serum activity of liver enzymes, such as alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and γ-glutamyl transpeptidase, as well as lipid profile alterations, also reflecting hepatobiliary commitment; (iv) derangement of iron metabolism, as shown through increases in serum iron, ferritin, haptoglobin and heme oxygenase-1 levels. In turn, elevated serum cystatin C, decreased urine creatinine output and increased urine microalbumin levels were detected upon exposure to tapentadol only, while increased serum amylase and urine N-acetyl-β-D-glucosaminidase activities were observed for both opioids. Collectively, these results are compatible with kidney injury. Changes were also found in the expression levels of liver- and kidney-specific toxicity biomarker genes, upon exposure to tramadol and tapentadol, correlating well with alterations in lipid profile, iron metabolism and glomerular and tubular function. Histopathological analysis evidenced sinusoidal dilatation, microsteatosis, mononuclear cell infiltrates, glomerular and tubular disorganization, and increased Bowman’s spaces. Although some findings are more pronounced upon tapentadol exposure, our study shows that, when compared with acute exposure, prolonged administration of both opioids smooths the differences between their toxicological effects, and that these occur at lower doses within the therapeutic range.

show abstract

“…The design of the experiment is schematically portrayed in Fig. 1 17 , then it was orally administered. The dose of zingerone 20 mg/kg b.w.…”

Section: Ethical Statement Animals and Dietarymentioning

confidence: 99%

Untitled

2021

IJPSR

View full text Add to dashboard Cite

Zingerone is an active phenolic acid and the least pungent component of Zingiber officinale. It is known to exhibit different pharmacological properties which include anti-inflammatory, antioxidant, anticancer and antimicrobial activities. But, so far there has been no information available on the role of zingerone in experimental breast carcinogenesis. The objective of this experiment is to untwine the anticancer qualities of zingerone against dimethylbenz (a) anthracene (DMBA)-incited mammary carcinogenesis. To achieve this goal, female Sprague-Dawley rats were arbitrarily classified into six groups. Group 1 was notified as the control, groups 2-5 were given a single dose of DMBA (25 mg/kg b.wt, subcutaneously) in the 4th week. Along with DMBA, groups 3 (initium), 4 (post-initium) and 5 (entire period) rats received zingerone (20mg/kg b.wt. p.o) every day in different time periods during the experimental period of 16 weeks. Group 6 rats received 20 mg/kg b.wt. of zingerone alone. Cancer-bearing animal mammary tissue when evaluated by western blot showed increased immune expression patterns of ER, PR, HER2/ neu, cyclin D1 and also antiapoptotic protein (Bcl-2) and decreased expression of the proapoptotic proteins (P53, P21, Bax, caspases 3 and 9. When zingerone (20 mg/kg b. wt.) supplementation was continued for the entire duration of the experiment to DMBA-treated rats, the expression patterns of various tumor and apoptotic markers including the pathological modifications were switched back to essentially normal. Therefore, we conclude that zingerone could be considered as a powerful chemo preventive agent to counter DMBA incited breast carcinogenesis.

show abstract

Antihyperlipidemic and antiapoptotic potential of zingerone on alcohol induced hepatotoxicity in experimental rats

Cited by 21 publications

References 47 publications

Zingerone prevents lead‐induced toxicity in liver and kidney tissues by regulating the oxidative damage in Wistar rats

Zingerone prevents lead‐induced toxicity in liver and kidney tissues by regulating the oxidative damage in Wistar rats

Repeated Administration of Clinical Doses of Tramadol and Tapentadol Causes Hepato- and Nephrotoxic Effects in Wistar Rats

Untitled

Contact Info

Product

Resources

About